Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.

Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.

Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.

SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.

A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.

The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.